Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Rudwaleit

Showing results (81-90 of 150) with videos related to

Pageof 15
Sort By:
Rheumatology (Oxford, England)|March 4, 2009
Adalimumab is effective and well tolerated in treating patients with ankylosing spondylitis who have advanced spinal fusionMartin Rudwaleit, Ignazio Olivieri, Kyriaki A Boki, et al.
Annals of the Rheumatic Diseases|May 16, 2025
Radiographic structural damage in axial spondyloarthritis: is there a preferred way to quantify progression over time? Comparison of blinded versus unblinded mSASSS scoringXenofon Baraliakos, Mikhail Protopopov, Valeria Rios Rodriguez, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 19, 2022
Treatment With Tumor Necrosis Factor Inhibitors Is Associated With a Time-Shifted Retardation of Radiographic Sacroiliitis Progression in Patients With Axial Spondyloarthritis: 10-Year Results From the German Spondyloarthritis Inception CohortMurat Torgutalp, Valeria Rios Rodriguez, Fabian Proft, et al.
Advances in Therapy|July 22, 2025
Ixekizumab Improves Signs, Symptoms, and Quality of Life in Patients with Axial Spondyloarthritis Irrespective of Symptom DurationVictoria Navarro-Compán, John D Reveille, Proton Rahman, et al.
Rheumatology Advances in Practice|April 9, 2025
BASDAI and ASDAS disease states in relationship to ASAS40 response: post hoc analysis of ixekizumab in radiographic axial spondyloarthritisMartin Rudwaleit, Victoria Navarro-Compán, Hagen Russ, et al.
RMD Open|August 29, 2024
Exploratory analysis of the potential disconnect between objective inflammatory response and clinical response following certolizumab pegol treatment in patients with active axial spondyloarthritisMartin Rudwaleit, Helena Marzo-Ortega, Victoria Navarro-Compán, et al.
Annals of the Rheumatic Diseases|December 22, 2011
High level of functional dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitisGisela Ruiz Heiland, Heiner Appel, Denis Poddubnyy, et al.
Annals of the Rheumatic Diseases|June 13, 2022
Treatment with tumour necrosis factor inhibitors is associated with a time-shifted retardation of radiographic spinal progression in patients with axial spondyloarthritisMurat Torgutalp, Valeria Rios Rodriguez, Ani Dilbaryan, et al.
The Canadian Journal of Cardiology|September 15, 2006
Brucella endocarditis in prosthetic valvesSascha Al Dahouk, Thomas Schneider, Andreas Jansen, et al.
Annals of the Rheumatic Diseases|June 28, 2012
Active inflammation and structural change in early active axial spondyloarthritis as detected by whole-body MRIChristian E Althoff, Joachim Sieper, In-Ho Song, et al.
Pageof 15

Showing results (81-90 of 150) with videos related to

Sort By:
Pageof 15
Rheumatology (Oxford, England)|March 4, 2009
Adalimumab is effective and well tolerated in treating patients with ankylosing spondylitis who have advanced spinal fusionMartin Rudwaleit, Ignazio Olivieri, Kyriaki A Boki, et al.
Annals of the Rheumatic Diseases|May 16, 2025
Radiographic structural damage in axial spondyloarthritis: is there a preferred way to quantify progression over time? Comparison of blinded versus unblinded mSASSS scoringXenofon Baraliakos, Mikhail Protopopov, Valeria Rios Rodriguez, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 19, 2022
Treatment With Tumor Necrosis Factor Inhibitors Is Associated With a Time-Shifted Retardation of Radiographic Sacroiliitis Progression in Patients With Axial Spondyloarthritis: 10-Year Results From the German Spondyloarthritis Inception CohortMurat Torgutalp, Valeria Rios Rodriguez, Fabian Proft, et al.
Advances in Therapy|July 22, 2025
Ixekizumab Improves Signs, Symptoms, and Quality of Life in Patients with Axial Spondyloarthritis Irrespective of Symptom DurationVictoria Navarro-Compán, John D Reveille, Proton Rahman, et al.
Rheumatology Advances in Practice|April 9, 2025
BASDAI and ASDAS disease states in relationship to ASAS40 response: post hoc analysis of ixekizumab in radiographic axial spondyloarthritisMartin Rudwaleit, Victoria Navarro-Compán, Hagen Russ, et al.
RMD Open|August 29, 2024
Exploratory analysis of the potential disconnect between objective inflammatory response and clinical response following certolizumab pegol treatment in patients with active axial spondyloarthritisMartin Rudwaleit, Helena Marzo-Ortega, Victoria Navarro-Compán, et al.
Annals of the Rheumatic Diseases|December 22, 2011
High level of functional dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitisGisela Ruiz Heiland, Heiner Appel, Denis Poddubnyy, et al.
Annals of the Rheumatic Diseases|June 13, 2022
Treatment with tumour necrosis factor inhibitors is associated with a time-shifted retardation of radiographic spinal progression in patients with axial spondyloarthritisMurat Torgutalp, Valeria Rios Rodriguez, Ani Dilbaryan, et al.
The Canadian Journal of Cardiology|September 15, 2006
Brucella endocarditis in prosthetic valvesSascha Al Dahouk, Thomas Schneider, Andreas Jansen, et al.
Annals of the Rheumatic Diseases|June 28, 2012
Active inflammation and structural change in early active axial spondyloarthritis as detected by whole-body MRIChristian E Althoff, Joachim Sieper, In-Ho Song, et al.
Pageof 15